Literature DB >> 33841651

MiR-22-3p suppresses cell growth via MET/STAT3 signaling in lung cancer.

Xia Yang1, Wenmei Su2, Yu Li3, Zhiqing Zhou3, Yi Zhou3, Hu Shan1, Xiaoling Han2, Ming Zhang1, Qiuhong Zhang1, Ying Bai1, Chunfang Guo4, Shuanying Yang1, David G Beer4, Guoan Chen3.   

Abstract

MiR-22-3p has been reported to be down-regulated in several cancers, but its expression pattern and roles in lung cancer is unclear. Given the crucial role of microRNAs in cancer progression, we examined the expression and function of miR-22-3p in lung adenocarcinoma. MiR-22-3p expression in lung cancer tissues and cell lines was measured by qRT-PCR. Cell proliferation was measured by WST-1 and colony formation assays were used to reveal the role of miR-22-3p in lung cancer in vitro. MiR-22-3p was notably down-regulated in lung cancer tissues as compared to normal lung tissues, but it was not associated with the clinical characteristics of tumor stage, differentiation and patient's smoking status. Colony formation ability and cell proliferation were suppressed by miR-22-3p mimics in lung cancer cell lines. Mechanistically, miR-22-3p mimics could reduce MET and STAT3 protein expression and induce apoptosis as measured by PARP protein. We conclude that miR-22-3p may play a tumor suppressor role via inhibiting MET-STAT3 signaling and have potential to be a therapeutic target and biomarker in lung adenocarcinoma. AJTR
Copyright © 2021.

Entities:  

Keywords:  MET; STAT3; lung cancer; miR-22-3p

Year:  2021        PMID: 33841651      PMCID: PMC8014426     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  49 in total

Review 1.  Targeting the Met pathway in lung cancer.

Authors:  Astrid Belalcazar; Daisy Azaña; Cesar A Perez; Luis E Raez; Edgardo S Santos
Journal:  Expert Rev Anticancer Ther       Date:  2012-04       Impact factor: 4.512

2.  miR-22 promotes HBV-related hepatocellular carcinoma development in males.

Authors:  Runqiu Jiang; Lei Deng; Liang Zhao; Xiangcheng Li; Feng Zhang; Yongxiang Xia; Yun Gao; Xuehao Wang; Beicheng Sun
Journal:  Clin Cancer Res       Date:  2011-07-12       Impact factor: 12.531

3.  Sex-specific, reciprocal regulation of ERα and miR-22 controls muscle lipid metabolism in male mice.

Authors:  Judith Schweisgut; Christian Schutt; Stas Wüst; Astrid Wietelmann; Bart Ghesquière; Peter Carmeliet; Stefan Dröse; Kenneth S Korach; Thomas Braun; Thomas Boettger
Journal:  EMBO J       Date:  2017-03-17       Impact factor: 11.598

4.  Proteomic analysis of eIF-5A in lung adenocarcinomas.

Authors:  Guoan Chen; Tarek G Gharib; Dafydd G Thomas; Chiang-Ching Huang; David E Misek; Rork D Kuick; Thomas J Giordano; Mark D Iannettoni; Mark B Orringer; Samir M Hanash; David G Beer
Journal:  Proteomics       Date:  2003-04       Impact factor: 3.984

5.  Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation.

Authors:  F Palacios; C Abreu; D Prieto; P Morande; S Ruiz; T Fernández-Calero; H Naya; G Libisch; C Robello; A I Landoni; R Gabus; G Dighiero; P Oppezzo
Journal:  Leukemia       Date:  2014-05-14       Impact factor: 11.528

6.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

7.  miR-22 represses cancer progression by inducing cellular senescence.

Authors:  Dan Xu; Fumitaka Takeshita; Yumiko Hino; Saori Fukunaga; Yasusei Kudo; Aya Tamaki; Junko Matsunaga; Ryou-U Takahashi; Takashi Takata; Akira Shimamoto; Takahiro Ochiya; Hidetoshi Tahara
Journal:  J Cell Biol       Date:  2011-04-18       Impact factor: 10.539

8.  A Novel Serum 4-microRNA Signature for Lung Cancer Detection.

Authors:  Ernest Nadal; Anna Truini; Asuka Nakata; Jules Lin; Rishindra M Reddy; Andrew C Chang; Nithya Ramnath; Noriko Gotoh; David G Beer; Guoan Chen
Journal:  Sci Rep       Date:  2015-07-23       Impact factor: 4.379

9.  Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma.

Authors:  Nayoung Kim; Hong Kwan Kim; Kyungjong Lee; Yourae Hong; Jong Ho Cho; Jung Won Choi; Jung-Il Lee; Yeon-Lim Suh; Bo Mi Ku; Hye Hyeon Eum; Soyean Choi; Yoon-La Choi; Je-Gun Joung; Woong-Yang Park; Hyun Ae Jung; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn; Hae-Ock Lee
Journal:  Nat Commun       Date:  2020-05-08       Impact factor: 14.919

10.  Discovery of an Indirubin Derivative as a Novel c-Met Kinase Inhibitor with In Vitro Anti-Tumor Effects.

Authors:  Karyn Muzinga Ndolo; Su Jin An; Kyeong Ryang Park; Hyo Jeong Lee; Kyoung Bin Yoon; Yong-Chul Kim; Sun-Young Han
Journal:  Biomol Ther (Seoul)       Date:  2019-03-01       Impact factor: 4.634

View more
  4 in total

1.  AC016405.3 functions as an oncogenic long non-coding RNA by regulating ERBB3 via sponging miR-22-3p in breast cancer.

Authors:  Min Wei; Jie Wang; Qi He; Lei Liu; Zhiwei Wang
Journal:  J Clin Lab Anal       Date:  2021-08-17       Impact factor: 2.352

2.  ETS Proto-Oncogene 1-activated muskelin 1 antisense RNA drives the malignant progression of hepatocellular carcinoma by targeting miR-22-3p to upregulate ETS Proto-Oncogene 1.

Authors:  Guozheng Pan; Jian Zhang; Faping You; Tao Cui; Peng Luo; Shuling Wang; Xiaomei Li; Qingzhong Yuan
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

Review 3.  MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential.

Authors:  Javaid Ahmad Wani; Sabhiya Majid; Zuha Imtiyaz; Muneeb U Rehman; Rana M Alsaffar; Naveed Nazir Shah; Sultan Alshehri; Mohammed M Ghoneim; Syed Sarim Imam
Journal:  Diagnostics (Basel)       Date:  2022-07-01

4.  miR-22 Suppresses EMT by Mediating Metabolic Reprogramming in Colorectal Cancer through Targeting MYC-Associated Factor X.

Authors:  Shusen Xia; Xianyan Wang; Yi Wu; Tong Zhou; Hongpeng Tian; Zuoliang Liu; Lifa Li; Zaihua Yan; Guangjun Zhang
Journal:  Dis Markers       Date:  2022-08-25       Impact factor: 3.464

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.